 NEW YORK, Aug. 31, 2022 GLOBE NEWSWIRE -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T iNKT cell therapies to treat cancer and other immune-mediated diseases, announced that the Company will participate in two investor conferences in September: 